Henderson Brothers, Inc.’s Post

➡️ Upcoming Webinar on Monday, August 5 ⬅️ The high cost of GLP-1 (glucagon-like peptide 1) drugs is straining employer healthcare budgets as they are increasingly used for treating obesity. With several more GLP-1 drugs expected to hit the market by 2026, and approvals for other medical conditions imminent, costs for employer health plans are likely to continue to rise. The increasing use of these drugs raises several challenges and questions for employers who need to develop the appropriate strategy for their organization. Join us as we discuss the dynamics of GLP-1 drugs including the history, development, and advancements of this drug class, current medications and the pipeline, trends in GLP utilization and cost, and various coverage and management strategies. > > Click here to register! https://lnkd.in/dcxsRzcm

Very proud to publish another article with results of daily work in Palliative Care. In this article, focused on the prescription, adequacy and deprescription of pharmaceuticals in patients with high clinical complexity at the end of life, we realize that it is essential that there is an individualized adjustment of pharmacotherapy, according to individual organic and global functionality and the trajectory of the diseases and the current moment of the patient and their family. Pro re nata ("as needed") medication is a key factor in ensuring well-being and safety in care at home, just as it is associated with death at home. Full article can be assessed here: https://lnkd.in/dS27cMJY with: Inês Rodrigues (1st author), João Rocha Neves and Marília Dourado #palliativecare #palliativemedicine #fmuc #fmup #ulsge

Colleagues, I am pleased to inform you that UroPharma has successfully completed another major step on the road to bringing our innovative #bladder drug-device #deliverysystem to market. From the perspective of #regulatory approval, we are now in the final stretch with, only one more hurdle to jump before we submit our intermittent drug-delivery device for the UKCA mark in order to launch in the UK market.   With the UKCA mark, the dtb-instilla will allow clinicians to provide intravesical (direct-to-bladder) drug delivery treatments to patients through a licensed device, providing better treatments whilst avoiding the major problems associated with the oral delivery of #antibiotics and other drugs for #bladdermanagement.   Human factors (HF) studies of the dtb-instilla intermittent device, both formative and summative, now have been completed in the UK. The latter one also validated that our instructions for use (IFU) document is suitable for incorporation with the product. Positive results on both of these aspects are compliance requirements for the device to enter the market. The conclusion from the latest study was that: “When considered as a whole, the test outcomes provide evidence that the dtb-instilla intermittent device can be safely and effectively used for intravesical administration of medication for bladder management”.   Our current intention is to launch the dtb-instilla onto the UK market in the first quarter of 2025 with only #biocompatibility studies ahead of us before we can submit for the UCKA mark we continue to seek #investment, so if you would like further information, especially given that we now have these positive results from the human factors studies, then please contact me.    The sooner we can get to market the sooner we can start helping patients who are suffering from the often life changing effects of bladder conditions and diseases and the sooner we can contribute to the overall campaign against #antimicrobialresistance that threatens the future of our #healthcare.

GLP-1 drugs like Ozempic are dominating the market and hitting employers with costs that can exceed $10,000 per person annually. Our analysis of over 80 billion medical records representing more than 320 million unique patients uncovers a growing trend: "wasteful" prescriptions from the bottom-ranking quartile of doctors. Key findings show: – Nearly 2% of the U.S. population uses GLP-1 drugs, and this figure could reach 10% by 2030. – High costs are often due to low-value prescriptions given to patients without chronic diseases or those who discontinue use within six months. – Effective management involves guiding employees to high-performing providers who prescribe GLP-1 drugs judiciously. To tackle this, our data scientists have integrated new metrics on effective GLP-1 prescribing practices into Garner’s data methodology. Utilizing the largest claims database available, Garner drives members to top-performing doctors with the lowest GLP-1 waste rate in their network, enhancing health outcomes while creating cost-reduction measures for employer medical trend. Learn how your business can navigate GLP-1 access and costs on our blog: https://lnkd.in/g8npcWkS

💡 Weight loss meds like GLP-1s are a breakthrough, but Big Pharma's pricing is a major roadblock! Discover how PBMs are stepping in with innovative programs to help manage costs and improve patient outcomes. Read more: https://lnkd.in/en23Pq_3

GLP-1 drugs have enormous implications not only for healthcare but also for the entire economy. You don't want to miss this important webinar on 7/23 to learn more about our findings.

This was an excellent article by 46brooklyn Research about the complexities of drug pricing. While many want to point the finger so simply at manufacturers for the high cost of drugs, it is ignorant and naive to do so. Why is this so complex? Because access to drugs are controlled by vertically integrated, administrative service organizations known as - insurers and PBMs. How do we simplify this? Get the manufacturers and the providers working together directly. Both are directly serving #patients interests. https://lnkd.in/gbnZUEMb

Another recent paper from our group (and a little different than our usual area of focus). Whanhui Chi used ten years of Medical Expenditures Panel Survey data to better understand drivers of drug costs in the US between 2011 and 2020. We identified that metabolic agent expenditures increased by over $40 billion annually over the course of the study period with insulin products accounting for $37.8 billion of $100.1 billion spent in the category in 2020. An emerging reliance on injectable products and expanding indications for antidiabetic agents is likely to continue to drive metabolic agent expenditures over the coming decade. Excellent work, Whanhui Chi and colleagues! https://lnkd.in/gcMnjjvM

Patients need better options for managing Alcohol Use Disorder (AUD) without the downsides of current treatments. Adial Pharmaceuticals is listening. Our approach minimizes side effects, avoids painful treatments, and reduces stigma, empowering individuals to manage their condition with dignity and without disrupting their lives. For more about Adial, please visit: https://bit.ly/4fNwY1V #HealthInnovation #AUD #AUDTreatments

Pharmaceutical medications aren’t your only option when it comes to your health. In my clinical practice, I prefer to use the least invasive, lowest risk options first, allowing you to feel comfortable with each and every treatment decision. Sign up for the Holiday Crash Course where you will be given the keys to help reverse Alzheimer at https://lnkd.in/gPimJiwW